- Home
- HMY vs ROIV Comparison
HMY vs ROIV Comparison
Compare HMY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HMY | ROIV |
|---|---|---|
| Founded | 1950 | 2014 |
| Country | South Africa | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HMY | ROIV |
|---|---|---|
| Price | $19.89 | $21.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $16.00 | ★ $24.31 |
| AVG Volume (30 Days) | 3.7M | ★ 8.2M |
| Earning Date | 02-04-2016 | 02-09-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ 67.74 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $4,161,584,110.00 | $20,329,000.00 |
| Revenue This Year | $40.10 | N/A |
| Revenue Next Year | $14.83 | $741.42 |
| P/E Ratio | $15.65 | ★ N/A |
| Revenue Growth | ★ 20.39 | N/A |
| 52 Week Low | $8.08 | $8.73 |
| 52 Week High | $22.25 | $23.47 |
Technical Indicators
Market Signals| Indicator | HMY | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 53.08 |
| Support Level | $19.76 | $21.36 |
| Resistance Level | $20.67 | $22.72 |
| Average True Range (ATR) | 0.75 | 0.80 |
| MACD | -0.17 | -0.13 |
| Stochastic Oscillator | 7.10 | 45.71 |
Price Performance
Historical ComparisonAbout HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.